WARNER-LAMBERT's HALLS COUGH TABLET IS FIRM's LEADING PRODUCT
WARNER-LAMBERT's HALLS COUGH TABLET IS FIRM's LEADING PRODUCT in terms of sales in 1983, according to W-L's annual report for 1983. "Halls, the leading cough tablet in the world, attained its highest U.S. market share in history," the company said. "Halls has become W-L's largest single selling product." The cough medicine has overtaken W-L's chewing gum business as the company's top seller. The chewing gum business is still heavily promoted overseas. To complement Halls, W-L has begun test marketing Mediguell, a "convenient" alternative to cough syrup, the company reported. "The good-tasting, chewable tablet delivers eight-hour cough relief in two-tablet dose, twice the effectiveness of regular strength liquids." Overall, W-L's non-Rx sales grew 3.8% to $842 mil. in 1983, while operating profit for the business segment was up 16.1% to $144 mil. The firm's largest business group, ethical pharmaceuticals, produced sales of $1.41 bil., up 9.2%. Operating profit for ethicals was ahead 10.1% to $185 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth